Toward a chronoimmunomodulation by cefodizime in multiple myeloma and chronic uremia.
Nine healthy subjects, 19 patients with multiple myeloma (MM) and 21 patients with chronic uremia were given cefodizime (2 g i.v.) at 2 different timepoints either in the morning or in the evening for 5 to 7 consecutive days. The following immunological parameters were comparatively evaluated before and after cefodizime administration: rosette-forming cells (RFC%), T lymphocyte subpopulations, monocyte chemotaxis index (MCI) and granulocyte chemotaxis index (GCI). Independently of the time of drug administration, a circadian rhythm was clearly detected (90% CI) as regards RFC%, CD3, CD4, CD8, CD4/CD8 before and RFC%, CD3, CD4, CD8, GCI after therapy. In addition, in patients treated at 0800 cefodizime increased the MESOR of the MCI and, to a lesser extent, of the GCI. The chronoimmunomodulatory effects of cefodizime in patients with MM and chronic uremia are discussed.
Carandente
F
F
Cattedra di Cronobiologia, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano, Italy.
De Vecchi
A
A
Halberg
F
F
Cornélissen
G
G
Dammacco
F
F
D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D002940:Circadian Rhythm / Q000187:drug effects*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology*; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology*; D012016:Reference Values; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology*; D014511:Uremia / Q000276:immunology*
D000276:Adjuvants, Immunologic; D002439:Cefotaxime; C033356:cefodizime